BridgeBio have demonstrably improved its development of an innovative therapy for amyloid heart disease, utilizing the compound. Initial trial results suggests promising outcomes for patients suffering with the https://biotech677938.blogaritma.com/39945315/company-advances-cardiac-amyloidosis-therapy-with-the-therapy